ifthese nonneurol eptic treatment alternatives and an attempt to establish someguidelines.for their use.
The cur re nt a pproac h to treatm ent of pati en ts wit h schizophreni a is a combinat ion of m edi cation a nd psych osocial int e rvention ; t his approach has yie lde d t he best res ults ( I). The efficacy of m edi cation is well d ocum e n t ed (2) , ye t up to 30% of patients wh o have had opt im um t ria ls of neu rol eptics co ntinu e to expe rie nce posit ive or negative sym pto ms, or di spl ay un con troll ed behavior (2) . Pa t ie nts wh o do not resp ond ade q uate ly to neuroleptics may be seve re ly impai red du e to pe rsiste n t sym pto ms . They may a lso develop significa nt side effects like t a rdive dyskinesia . It is, th e refore, ext re me ly importa n t th a t alternat ive t hera pies be d eveloped to br ing th ese sym p to ms und er co n trol. Seve ra l t ri al s invo lving non ne urole pt ic agents ha ve been carrie d o ut with va rying results. Can t hese resu lts be exte nde d to involve all neurol eptic resist ant pati ents? How does one decid e which pa ti e n t to match with whi ch dru g? This paper is a n a t te m pt to t ry to a nswer t hese q uest ions a nd al so to review th e th erap eutic modaliti es avail abl e for th e neu roleptic resis tant pa tient.
Kane e t al (3) defin ed neuroleptic resist ance as occurring in a pati ent who cont inued to expe rie nce sig nifica n t impairm ent fro m sym p to m s of the illn ess in spite of trials of at least 3 different neuroleptics, from 2 di fferent che m ica l cla sses, for six weeks each , in doses of up to 1,500 m gs of ch lor pro m az ine eq uiva lent, over th e last 5 ye a rs, a fte r organi c pathology had been rul ed ou t. This defini tio n of resist a nce a ppears to be co m pre he nsive and is wid ely used . Sho uld blood levels be a part of th e definition of resistance? At this stage, testing for blood levels of ne uroleptics is not routinely us ed in clinical se t t ings because both act ual resul ts a nd test ing t echniqu es Sajiv J ohn, M.D . is a PGY-3 resid ent in t he Dep artm en t of Psychi a t ry a t th e U nivers ity of C hicago. Atul Mahab leshwarka r, M.D . is an In struct or in t he De part me nt of Psych iat ry a t Fin ch U nive rs ity of H ealth Scie nces in C hicago.
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NON-N EURO LEPTIC PHARMACOTHERAPY OF SC HIZO PHRENIA 23 have not been cons iste n t. Future definiti on s of neu rolep t ic resistance may well includ e blood level crite ria.
Th e t e rm neuroleptic origina te d fro m "ne uroleptanalgesia"-a form of sho rt ac t ing a nest hesia co m bin ing a n opia te de riva tive, fentanyl, and an antipsych ot ic, drop eridol (4) . The t erm has since co me to refer to a n ag ent that ha s both an a n t ipsyc ho t ic effec t a nd a n ex t ra pyra m idal side effect profile (E PS). This review focu ses o n drugs that a re not st rictly neuroleptics-sp ecificall y, drugs that have been shown to have a n tipsyc hot ic effec t, but no sig nifica n t EP S profile .
L ithium
Studies have shown that adding lithium to a neurol eptic ca n help treatm ent resist ant pati ents. W e look ed a t seve ra l whi ch were eit he r important reviews (5) , o r st ud ies th at have used RD C crite ria (6) and sing le blind (7) or doubl e blind d esigns (8, 9) with cro ssove r ph as es using placebo , for a tot al of a t least four wee ks each. The usu al se ru m levels of lithium in th ese trials have ran ged from 0.9-1.2 me qs / liter and th ey have last ed from 3-5 wee ks. Improvem ent in pati ents was docu men t ed in th e foll owing areas: psych otic sym pto ms , coo pe ra t ion, social compe te nc e, neatness, irritability, a nd exc ite me n t (9) . Lithium a lone was in feri o r to ne uroleptics in th e ac u te ly ill pati ent, th ou gh it is useful as a n adj unc t in schizo phrenia or schizoaffective d iso rde r (5,9) . Affec tive sym pto ms need not be present for im provem e n t to occur, th ou gh pr esen ce of a ffect ive sym pto ms may pred ict a bett er response to treatm e nt wi t h lithium. Respon se to lith ium does not mean a ne ed to cha nge th e diagnosis to a mood di sorder. Lithiu m may decrease chronic symptoms and ma y d ecr ea se th e ra te of rel apse by as mu ch as 30% in sc hizoaffective illness (8) . Th ere were a few ea rly reports of a reversibl e d elirium wh e n lithiu m was combined with high do ses of neuroleptics ( 10) . Th ese have been shown to be co m plete ly revers ible wh en th e drug was discontinued a nd now a ppear to have been cases of neuroleptic malignant syndrome.
In co nclus ion, adding lithium to neurol eptics in treatm en t res istant patient s ca n result in d ecr eas ed psych oti c sym p to ms, exc ite me n t, irrit a bili ty a nd possibly ra t es of relapse . Pr esen ce of affective sym pto ms appears to pr edi ct be tt er res ponse in th ese patients.
Beneodiazepines
Our review of th e lit erature reveal ed 15 doubl e-blind st ud ies of th e us e of benzodiazepines in schizophrenia. Only four (11-1 4) us ed DSM -III ( 15) a nd /or RDC crite ria for diagnosis, had doubl e-blind d esi gn s with placeb o crossove rs and last ed from 2-8 weeks . T ypi call y benzodiaz epines a re used in co nj unc t ion wit h ne urolept ics, a nd st ud ies have shown decr eased hostility, t en sion , exc ite me nt, an d incr eased spo n ta neous soc ia l e ngage me nt (11 ,1 2). Sp ecific benzodi a zepines studied includ e alprazola m ( 12, 14) , di az ep am , chlord iaze po xide ( 13, 14) , a nd estazolam ( I I). Lon ger ac ting drugs lik e di az ep am a nd chlord ia ze po xide a re sa fe r, as t hey generall y have J EFFER SO N J O URNAL OF PSYCHI AT RY mild er withd rawal sym p toms. Be n zod ia zepines hav e usu all y been used d uring exace rbation s of psychosis to d ecreas e agita t ion . Be nzod iaze pines mu st be used ca refully d ue to the po ten tial problem s of abus e, withdraw a l sym p to ms incl uding sei zu res a nd occa sion a l soci a l d isin hibi tio n.
In ad d it ion to clinica lly available benzodiazepines, GABA mim etic a ge n ts an d pa rtial ben zodi a zepin e agonists have a lso been st ud ied expe r im e n tally. In t heory, t hes e agen ts shou ld prod uc e a nx iolyt ic and anticonvulsant e ffec ts wi th out th e se da t ive and muscle re laxan t e ffec ts of benzodiaz epin es . It is a lso a n t icipa te d t hat they mi ght produ ce d ecreas ed C NS d epressant ac t ivity with red uced toxi cit y in th e ove rdose sit ua t ion, lack of pot enti at ion of alcoho l e ffec ts, and red uced ph ysica l d ependence and a bus e lia bility. Mu scimol , a GABA mim etic, was found to aggrava te psych otic sym p toms, whi le oth ers, in cluding tet rahydroisox a zol op yr id inol, gammaacetylenic GABA, ga m m a vin yl GA BA, and progabid e , have been show n to produce no e ffec t in sc hizo p h r e nia . Pa r t ial a gonist s, includin g abccarnil , a lpi d c rn, d ival on , an d b r et az en il, have be en st udied , wi t h on ly b ret az eni l (up to 4.5 m gs /d ay) producin g an y effec t. It produced a 40 % d ecr ea se in BPRS scores, effect s on bot h positi ve a nd nega tive symptoms, no EPS and mild se d a t ion when g ive n to 11 6 pa ti ent s for 3 wee ks (26) . Benzodiazepin es have also proved useful in treating so m e o f th e sid e e ffects of neuroleptics like akathisia, tardive dyskin esia, and dyst onia (2) . U nfortun a t e ly, most st ud ies o f th e us e of benzodiazepines in patient s with sc h izo p h re n ia have used ve ry sm a ll sa m ple siz es, thus lim iting th e co ncl us io ns th at ca n be drawn fro m th em.
In co ncl usio n, benzodiazepines ca n be e ffect ive in treating ce rt a in neuroleptic sid e e ffec ts, and th ey m ay a lso have a ro le to pl ay wh en co m bined with ne u rol e pt ics in patients who displa y anx iety, ps ychosis, or a gitation not r esp ondin g to conve n t ional ne urol ep tics a lon e. GA BA m im etics and partial benzodiaz epine agon ists have not cons istent ly been show n to be e ffec t ive in studi es to d at e . However, th e o ne e nc ou ra ging re por t on bre tazen il a nd th e m uch bett er side effec t profile of th e g roup in gen eral ma ke furth er r es earch in this a re a imperative .
Carbamaeepine
Tri a ls with ca rba m aze pine in schizo p h re n ia a re fairly new a nd t he dr ug is typi ca lly us ed in a d d it io n to neuroleptics. Of 5 d oubl e-blind st ud ies of th e use of ca rba m a ze pine in patien ts with sc hizo p h re n ia, three a re su pe r ior, uti lizin g OSM-III or RO C cr ite r ia for the d iagnosis of sc hizo p h re nia , the crossove r form a t with pla cebo, standard rating sca les, a nd serum ca rba m a ze pine level s between 5-18 mcgs/ml (16) (17) (18) . T r ial s have last ed 4-6 wee ks. In neuro leptic refra ctory pati ent s, ca rba mazepine has be en shown to d ecr eas e exc ite me n t, mania lik e sym p to ms , s uspi ciousness , violen ce , and aggression . C arbamazepine has a lso been shown to be use ful in nonepi leptic schizophrenic pati ents with t empora l lob e EEG a b no r ma lit ies, wit h suc h pat ient s showing d ecreased aggres siv e a ct s a nd improved se lf-co n t ro l in int erpe rsonal sit ua t ions ( 17) .
Th ese studi es see m to suggest that any e ffect of ca rba mazepine on psych ot ic symptoms is mod est. Th e main ben efit of ca rba m a ze pine in pati ent s with schizoph re-ni a may be in decr easi ng aggress ion, ove rac t ivity, a nd improving co nt ro l in int erperson al sit ua tio ns .
Propranolol
Initial trials of propran olol in schizophreni a were received wit h e nt hus iasm, how ever lat er work has not been as e ncou rag ing. Pr opran olol has bee n used in com bina tio n with neurolcptics, initi all y th e ra cemic (d- (20) . Some authors have postulated th ese as th e m echanisms of ac t ion, inst ead of a primary a n tipsycho t ic effec t (2) .
These st ud ies sugges t th at an y a nt ipsyc ho tic effec t of propran olol is a t best sligh t a nd m ay be rel at ed to it s ben eficial ph armacokinetic int e ract ion s or to a de cr eas e in a ka t h isia. This, a long with it s side effec t pro file, make it a limi t ed adj unct for pati en ts with treatm ent resist ant sch izo phre nia .
Clozapine and Other Novel Antipsychotic Drugs
Cl ozapin e first a ppe a re d in th e 1970's in Europe as a n a n ti psyc ho t ic st ruct urally relat ed to loxapin e and effec t ive in a subg rou p of treatment resist ant pat ie nt s. It th en disappeared for seve ra l years followin g seve ra l report s of ag ra nu locytosis occurring with th e drug, but ha s recently e me rged ag a in following severa l ca re fu lly cond uc te d studies (2, 3, (23) (24) (25) (26) . Up to 30% of treatm ent resist ant pat ients have shown subs ta nt ia l improvem ent in positive an d negative sym ptoms an d on global rating sca les wh en give n clozapine in doses ran gin g from 300-600 mgs pe r day for up to 6 wee ks. The dru g see ms to have m esolimbic a nd co r t ica l spec ificity, th erefore it is assoc ia te d with a very low incid en ce of Parkinsoni an sym p to ms a nd tardive dys kin esia . It a ppe a rs to act by influ en cin g multipl e neurotran smitt er sys te ms . It has an a n t icho line rgic a nd antihistaminic effec t, is a n a n tago nist a t 5HT2 a nd 5HT3 receptors, has an antiadrenergic action, a D I and D3 a lo ng with some D2 blockin g action at dopamine receptors and a lso incr eases dopamine rel ease in th e mesocor t ical syste m . Its effect on 5HT2 a nd 5HT3 recept ors a nd it s a bility to incr eas e dopamine rel eas e in th e m eso cortical syste ms m ay underlie it s effects on nega t ive sys te ms . A major side effec t includes agranulocyt osis, whi ch was ini ti all y see n in up to 13% of pati ents, a nd whi ch is now beli eved to occ u r in a bo ut 1.6% of pat ients on th e drug for more th an on e year. This effec t is reversibl e if th e dru g is discont inued . W eekl y whit e blood ce ll coun ts are advise d a nd th e maximum risk peri od is bel ieved to be between 6 weeks and 6 months. Other side effec ts include se izures in dos es
gre a te r th an 600 mgs pe r d ay, hyp ert ension a nd sia lor r hea, t he last two bein g at ypi cal for an a gent with antiadrenergic a nd a n t icho linergic action.
An tidepressants " De pression" in schizophre nia is co m mo n wit h up to 50% of first episode patien ts and 30% of chronic patients m eeting crite ria for major depression a nd 10% of schizophrenics dying of su icide (27) . However , wh at constitu tes "depression" in schizophrenics ca n be difficult to assess as organic factors , includi ng a ne m ias , ca nce rs, endocrine a nd neurological di sorders a nd m edi cat io ns, negative symptom s, drug induced a kines ia a nd ak athisia, cog nit ive cha nges a nd pa rt ia l insight int o th e nature and co nse q ue nces of th e illn ess a re a ll ca pa ble of m im icking depression . Depression m ay a lso be prominent in th e prod rom e of psychot ic relaps e and in schizoaffective dis order. Tw o m aj or a r t icles have reviewe d th e ro le of antid epressants (tricyclics, MAO inhibitors a nd possibl y lithium ) in schizop h re nia (27, 28) . Furth er, Siris (29) has very recently r eviewed th e assess me n t a nd t reatment of depressi on in sc hizo phre nia. Th ese reviews sugges t th at a nt idepressan ts have a role in th e treatm ent of d epres sion in schizo ph re nia a fte r th e confo undi ng factors mention ed ha ve been rul ed ou t.
Antidepressants have pr odu ced bette r res ults in outpatients ra th er th an in inpat ients a nd in patients who a re not ac t ively psych o ti c. Most st udi es ha ve use d doses co m pa ra ble to those used in pr im a ry depression, and t ri al s have lasted a t lea st six week s. Dir ect co m pa risons of di fferent tricyclic a nt ide pressants or of tri cyclics with ot he r antid epressants have not been repo r t ed. Siris (29) recomm ends th at th e dose of th e a n t ide p ressa nt be g rad ually incr eased a nd th at th ey be us ed in com binati on with ong oing neuroleptic and a n tipar kinso nia n t reat m e n t. Long-t er m maint enance treatment m ay be ben eficial for th e patie nt wh o responds favora bly init iall y. Antidepressants have no t been shown to be effec t ive for nega tive symptoms. Most re po rted double blind placebo con tro lle d tria ls have invo lved t ri cyclic antid epressa n ts . H oweve r, sca t te re d pr elimina ry rep orts sugges t t hat monoamine oxidase inhibitors a nd se lec t ive sero to nin reupt ak e inh ibit or s may be effective as well (29) . It sho uld be not ed th at wh en t ri cyclics are used wit h an t ipsychot ics, t he blood levels of both d rugs ca n inc re ase as ca n th e a ntic ho line rgic effect. T herefore , an y improvem ent not ed m ay be spurious.
L-Dopa and Reserpine
Our review reveal ed four st ud ies assessing th e ro le of L-dopa in schizophreni a , mo st of whi ch wer e ca r ried ou t in th e 1970's a nd in which pa ti ents were diagnosed without using sta ndard ized criteria . A fur th er limit ation is t hat follow-up has been based on a globa l clinical impression a nd not st a ndardize d ra t ing scales. Trials have us ed dos es between 300-2000 m gs per day for 6-8 wee ks, usually com bine d with neuroleptics and a peripheral dop ad ecarboxyla se inhibitor. St ud ies (2,30) sugge st that chro nic patients with negative sym pto m s, usu all y hospit al ized a nd refra ctory to treatment, ca n show som e incr eased ac t ivity, ale r t ness, socia l co n tact a nd motivation. Sid e effects of L-Dopa in this population significantly limit it s use. T hese include worsening of psychotic sym pto ms , agitation, and drug-indu ced dysk inesias. More res earch is ne eded as L-Dopa may be useful in patients with neg at ive sym ptoms, and this subgroup has proved refractory to most drug trials.
Res erpine (2, 31) was the first drug to prove effec t ive in treating pati en ts with psychosis and was wid ely used prior to th e introduction of neuroleptics in t he 1950's . Our review of th e lit erature rev ealed a total of 8 studies asse ssing th e effectiveness of res erpine in schizophrenia. The best of th es e (3 1) used a tot al of 120 pati ents, lasted 6 months and co m pa red reserpine 2 mgs/day versu s chlor pro maz ine 200 mgs/day and placebo. In doses of 2-12 mgs per da y for up to 6 week s, patients have shown modest improvem ent in positive sym p to ms and inte r pe rso nal functi oni ng. Signi ficant side effec ts of reserpine includ e depression , hypot ension, a nd exace rba t ions of asthma and peptic ulc er. Sin ce both res erpin e and antipsych oti cs ac t by d ecreasing DA transmission, it may not be effective in neuroleptic resist ant pati ents. Th e major limitation here is th e lack of recent lit erature and th e side effec ts of th e drug which limit it s us efulness in schizophrenia.
Other Non-Neuroleptic Drugs
Man y o t he r age n ts have been tri ed as alte rna tive treatm en ts in neu rol e ptic resist ant schizo phre nics. For man y like ba clofen (32), bet aen dorphi n (33) , calcium cha nne l antagonist s (34) , cho lecys to kinin-like age nts (35) , megavit am ins (36), bromocript ine (37) , a pom or ph ine (38) , naloxone a nd naltrex on e (39, 40) , and t hyrotropin rel easing hormone (41) , th e majority of con t ro lled studies have not doc umen ted sustained efficacy. For others lik e valproat e (42) , va sopressin (43), a nd clo nid ine (44 ), eit he r doubl e blind data are too pr eliminary, or sid e effec ts lik e postural hypot en sion o r fluid ret ention do not allow eve n pr eliminary conclus ions .
Conclusions
Our review of th e lit erature sugges ts that th e best way to m an a ge th e t rea t me nt resistant sc hizoph re nic is to identify th e persisting sym ptoms a nd th en apply various treatment options. For patients with persisting positive sym pto ms, drugs to be conside re d include clozapine, lit hium , benzodiaz epines a nd ca r ba maze pine. For patients with mainly negative symptoms, drugs to be conside re d include cloza pine and alprazolam. If pa t ie nts display pr edominant aggression and poor impulse cont ro l secondary to positive symptoms, treat with drugs shown us eful for positive sym pto ms. If aggression and poor impulse con t ro l occurs ind ependently, drugs th at ca n be used include ca rba m a ze pine, beta blo ckers, lithium, and possibl y sero to ne rg ic agen ts in light of evide nce linking se ro to nin dysfunction with viole nce a nd aggression. It is best to avoid benzodiazepin es in this group as th ey ca n lead to disinhibit ed be havior. Figure I below summarizes the rol e of non-neuroleptic pharmacothe rap y in neuroleptic resist ant schizophrenic patients.
I
De fine sch izop hrenia using standardized criteria suc h as DSM-III-R
I I I
Ad equat e trial of neuroleptics I I Resistan ce-s-d efi ne using com p re he ns ive cri ter ia , su ch as Kan e e t a l (3)
->:
Id cntify sid e-effects a nd tes t : Consider EEG : tri al of I. Pa rkinsonism -antich olincrgics (tre mor ); ca r ba mazc pi nc a m a n tad ine (rigid ity a nd a kinesia) / 2. Ak ath isia-ben zodi zapincs or bet a blockers 3. Tardive dyskinesia-adj ust dos e of an ti psychoti cs/an t icho linergics, bcn zodi a zepines, te t rab en a zin e , e tc .
/
Sym ptoms pe rsisting-idcn t ify spec ific ta rget sym p to ms a nd ad d one of thc drugs be low, a lways co m bin ing with psychosocial th crap y.P There a re se ve r a l ge ne r a l princi pl e s t o b e ke pt in m ind whe n using thes e a g ent s. With th e exce p t io n of c1ozap ine , m o st s hou ld be co m b ine d wi t h n euroleptics . They s h o u ld b e introduced g rad ually, a n d side effects s hou ld be monitored and treat ed e a rly. Drugs s h o u ld b e c ha nged, o ne at a time if n e eded , aft er id e n tifying s pecific target sy m p t o m s and monitoring cha nges carefu lly . Always d iscu ss th e r is ks and b enefit s with the patient a n d ca re fu lly d ocum ent it in the chart (2, 25) . Essentially, th ese arc th e principl es o f good pharm a cotherapy.
Sch izo p h re n ia, es pecia lly tre atm ent resis t a n t illn ess, is hard to treat. Som e o p t io ns for pharmacothe r apy d o ex is t. Th ese o p tio ns can b e implem ent ed log ica lly a n d a re b e st d one a fte r id entifying s pecific ta rget symptoms. Further re search in this a rea is clearly n e eded.
